Cargando…
Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma
PURPOSE: We aimed to evaluate the value of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT for the diagnosis of recurrent soft tissue sarcoma (STS), compared with [(18)F]FDG PET/CT. METHODS: A total of 45 patients (21 females and 24 males; median age, 46 years; range, 18–71 years) with 13 subtypes of STS underwent...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206606/ https://www.ncbi.nlm.nih.gov/pubmed/35113192 http://dx.doi.org/10.1007/s00259-022-05700-4 |
_version_ | 1784729366833397760 |
---|---|
author | Gu, Bingxin Liu, Xin Wang, Shuoer Xu, Xiaoping Liu, Xiaosheng Hu, Silong Yan, Wangjun Luo, Zhiguo Song, Shaoli |
author_facet | Gu, Bingxin Liu, Xin Wang, Shuoer Xu, Xiaoping Liu, Xiaosheng Hu, Silong Yan, Wangjun Luo, Zhiguo Song, Shaoli |
author_sort | Gu, Bingxin |
collection | PubMed |
description | PURPOSE: We aimed to evaluate the value of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT for the diagnosis of recurrent soft tissue sarcoma (STS), compared with [(18)F]FDG PET/CT. METHODS: A total of 45 patients (21 females and 24 males; median age, 46 years; range, 18–71 years) with 13 subtypes of STS underwent [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT examination within 1 week for assessment local relapse or distant metastasis. Positive lesions on PET/CT images were verified by biopsy or 3-month follow-up. Wilcoxon matched-pairs signed-rank test was used to compare the semiquantitative values (SUV(max) and TBR) of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 in tumor lesions, and McNemar test was applied to test for differences of both tracers. RESULTS: Among the 45 patients, 282 local relapses and distant metastases were identified. Compared to [(18)F]FDG, [(68) Ga]Ga-DOTA-FAPI-04 PET/CT detected more lesions (275 vs. 186) and outperformed in sensitivity, specificity, PPV, NPV, and accuracy for the diagnosis of recurrent lesions (P < 0.001). [(68) Ga]Ga-DOTA-FAPI-04 demonstrated significantly higher values of SUV(max) and TBR than [(18)F]FDG PET/CT in liposarcoma (P = 0.011 and P < 0.001, respectively), malignant solitary fibrous tumor (MSFT) (P < 0.001 and P < 0.001, respectively), and interdigitating dendritic cell sarcoma (IDCS) (P < 0.001and P < 0.001, respectively). While mean SUV(max) and TBR presented favorable uptake of [(18)F]FDG over [(68) Ga]Ga-DOTA-FAPI-04 in undifferentiated pleomorphic sarcoma (UPS) (P = 0.003 and P < 0.001, respectively) and rhabdomyosarcoma (RMS) (P < 0.001 and P < 0.001, respectively). CONCLUSION: [(68) Ga]Ga-DOTA-FAPI-04 PET/CT is a promising new imaging modality for recurrent surveillance of STS, and compares favorably with [(18)F]FDG for identifying recurrent lesions of liposarcoma, MSFT, and IDCS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05700-4. |
format | Online Article Text |
id | pubmed-9206606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-92066062022-06-20 Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma Gu, Bingxin Liu, Xin Wang, Shuoer Xu, Xiaoping Liu, Xiaosheng Hu, Silong Yan, Wangjun Luo, Zhiguo Song, Shaoli Eur J Nucl Med Mol Imaging Original Article PURPOSE: We aimed to evaluate the value of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT for the diagnosis of recurrent soft tissue sarcoma (STS), compared with [(18)F]FDG PET/CT. METHODS: A total of 45 patients (21 females and 24 males; median age, 46 years; range, 18–71 years) with 13 subtypes of STS underwent [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT examination within 1 week for assessment local relapse or distant metastasis. Positive lesions on PET/CT images were verified by biopsy or 3-month follow-up. Wilcoxon matched-pairs signed-rank test was used to compare the semiquantitative values (SUV(max) and TBR) of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 in tumor lesions, and McNemar test was applied to test for differences of both tracers. RESULTS: Among the 45 patients, 282 local relapses and distant metastases were identified. Compared to [(18)F]FDG, [(68) Ga]Ga-DOTA-FAPI-04 PET/CT detected more lesions (275 vs. 186) and outperformed in sensitivity, specificity, PPV, NPV, and accuracy for the diagnosis of recurrent lesions (P < 0.001). [(68) Ga]Ga-DOTA-FAPI-04 demonstrated significantly higher values of SUV(max) and TBR than [(18)F]FDG PET/CT in liposarcoma (P = 0.011 and P < 0.001, respectively), malignant solitary fibrous tumor (MSFT) (P < 0.001 and P < 0.001, respectively), and interdigitating dendritic cell sarcoma (IDCS) (P < 0.001and P < 0.001, respectively). While mean SUV(max) and TBR presented favorable uptake of [(18)F]FDG over [(68) Ga]Ga-DOTA-FAPI-04 in undifferentiated pleomorphic sarcoma (UPS) (P = 0.003 and P < 0.001, respectively) and rhabdomyosarcoma (RMS) (P < 0.001 and P < 0.001, respectively). CONCLUSION: [(68) Ga]Ga-DOTA-FAPI-04 PET/CT is a promising new imaging modality for recurrent surveillance of STS, and compares favorably with [(18)F]FDG for identifying recurrent lesions of liposarcoma, MSFT, and IDCS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05700-4. Springer Berlin Heidelberg 2022-02-03 2022 /pmc/articles/PMC9206606/ /pubmed/35113192 http://dx.doi.org/10.1007/s00259-022-05700-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Gu, Bingxin Liu, Xin Wang, Shuoer Xu, Xiaoping Liu, Xiaosheng Hu, Silong Yan, Wangjun Luo, Zhiguo Song, Shaoli Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma |
title | Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma |
title_full | Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma |
title_fullStr | Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma |
title_full_unstemmed | Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma |
title_short | Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma |
title_sort | head-to-head evaluation of [(18)f]fdg and [(68) ga]ga-dota-fapi-04 pet/ct in recurrent soft tissue sarcoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206606/ https://www.ncbi.nlm.nih.gov/pubmed/35113192 http://dx.doi.org/10.1007/s00259-022-05700-4 |
work_keys_str_mv | AT gubingxin headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT liuxin headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT wangshuoer headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT xuxiaoping headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT liuxiaosheng headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT husilong headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT yanwangjun headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT luozhiguo headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma AT songshaoli headtoheadevaluationof18ffdgand68gagadotafapi04petctinrecurrentsofttissuesarcoma |